



**Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group**

Summary of Main Points from the Meeting held on Monday 24th July 2017

2. Minutes and Summary Notes from last meeting

The Minutes and Summary notes from the June 2017 Medicines Group meeting were approved and will be circulated.

3. Matters Arising

The Group noted the matters arising from the previous meeting.

4. Business to be transacted by the Medicines Group

4.1 Formulary Applications

Full applications

• **Fosfomycin 40mg/ml Injection (Fomicyt[®])**

Requested by the Microbiology Team for the management of

- Acute osteomyelitis
- Complicated urinary tract infections
- Nosocomial lower respiratory tract infections
- Bacterial meningitis
- Bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.

Fosfomycin oral is currently included on the formulary.

Only to be used on recommendation by Microbiology

Decision: Approved for addition to the formulary

• **Isavuconazole 100mg Capsules and 200mg Injection (Cresemba[®])**

Requested by the Microbiology Team the treatment of:

- Invasive Aspergillosis
 - Mucormycosis in patients for whom amphotericin B is inappropriate
- NHS England has advised its use in place of Posaconazole for rare moulds acquired from other hospitals. This is commissioned by NHS England and more cost effective than Posaconazole. Only to be used on recommendation by Microbiology

Decision: Approved for addition to the formulary

• **Ceftazidime 2g / Avibactam 0.5g Injection (Zavicefta[®])**

Requested by the Microbiology Team the treatment of hospital acquired infections with multi-drug resistant Gram negative organism with Klebsiella pneumoniae carbapenemase (KPC) plasmid. Indications include urinary, intra-abdominal and respiratory source infections. Only to be used on recommendation by Microbiology

Decision: Approved for addition to the formulary

Ex-Panel Requests

• **Sodium Hyaluronate Injection 1% 10mg/ml (1ml) syringe**

Requested by Podiatry Department WMUH for injecting Big Toes to treat joint pain. Currently use the version that is used to treat knees (40mg/2ml syringes). This results in half to third of the injection being wasted. The smaller 10mg/1ml syringes mean less wastage and less cost.

Cost comparison:

40mg/2ml syringe costs: £84 (Inc. VAT)

10mg/1ml syringe costs: £23 (Inc. VAT)

Potential cost saving of: £7,000 per annum based on 120 syringes used to treat toes per year.

Decision: Approved for addition to the formulary

4.2 Trust Medicines Policy



Chelsea and Westminster Hospital NHS Foundation Trust Trust Medicines Group

- **Trust Medicines Audit 2017 - Standards**

Standards for the Trust Medicines Policy Audit 2017. There were approved at the June meeting but have been subsequently updated to include a standard relating to a FP10(HP) prescription pads in light of CQC visit and indication in the PIR document that CQC will be seeking assurance of good governance being in place for controlled drugs as well as controlled stationary.

Decision: Approved

- **Trust IV Administration Guide - Updates**

Update to the Trust IV Administration Guide relating to:

- Urokinase (New)
- Epoprostenol (Update on account of the change in the formulation)

Decision: Approved

4.3 Medicines Optimisation

- **Richmond CCG Prescribing changes**

It was noted that a decision has been taken at Richmond CCG that the CCG will no longer support the routine NHS prescribing of the following products:

- Gluten Free Food
- Vitamin D Maintenance
- Medicines that are available OTC

Decision: Noted

- **Medicines Optimisation Strategy**

DL has drafted a Medicines Optimisation Strategy for the Trust for 2017-2020. This document sets out the aspirations the Trust and the corresponding objectives that the Trust needs to undertake to achieve these.

Decision: Due to late circulation, Comments on this document to be forwarded by Monday 31st July.

4.4 NICE TA Guidance

NICE TA Guidance - June 2017

10 Appraisals were published in June 2017

TA447 - Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Action: Update formulary accordingly

TA448 - Etelcalcetide for treating secondary hyperparathyroidism
Action: To confirm if relevant to C&W

TA449 - Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Action: Nil - Not relevant to C&W

TA450 - Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia
Action: Nil - Not relevant to C&W

TA451 - Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
Action: Update formulary accordingly



**Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group**

TA452 - Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (Terminated appraisal)

Action: Nil - Appraisal Terminated

TA453 - Bortezomib for treating multiple myeloma after second or subsequent relapse (Terminated appraisal)

Action: Nil - Appraisal Terminated

TA454 - Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (Terminated appraisal)

Action: Nil - Appraisal Terminated

TA455 - Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people

Action: Update formulary accordingly

TA456 - Ustekinumab for moderately to severely active Crohn's disease after previous treatment

Action: Update formulary accordingly

4.5 IVIG Update

- **IVIG requests**

June 2017

CWH Site

There were 15 IVIG issues, with 3 new requests

WMUH Site

There were 13 IVIG issues, with 3 new request

Decision: Approved

4.6 Items for noting

- **NHS England - Prescribing and dispensing of Pregabalin**

Letter from NHS England re prescribing and dispensing of Pregabalin which instructs that there is no longer a need to differentiate between the branded and non-branded product on prescribing and dispensing systems following the imminent expiry of the patent on Lyrica[®] for its Neuropathic pain indication.

Decision: Noted

- **NHS England - Obeticholic acid for treating primary biliary cholangitis**

Letter from NHS England re. Obeticholic acid for the treatment of Primary Biliary Cholangitis which details the specialist centres that are commissioned to initiate Obeticholic acid.

Decision: Noted

- **PGD Trackers - C&W and WMUH**

PGD Trackers for C&W and WMUH Sites. It was explained that there is extensive work ongoing to harmonise GUM PGDs across C&W, Sexual Health Sutton and Sexual Health Hounslow.

Decision: Noted

- **Medicines Group & Medicines Safety Group - Sub-Group Report to the Patient Safety Group**

Report for Medicines Group & Medicines Safety Group to the Patient Safety Group



**Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group**

Decision: Noted

- **Audit Tool Assessment Calculation**

Audit Tool Assessment for calculation of the APAT score for audits planned to be undertaken in the Trust.

Decision: Noted

- **Pharmacy Audit Plan 2017-18**

Pharmacy Audit Plan 2017-18 including APAT scores.

Decision: Noted

- **Audit: Omitted and delayed medicines**

Audit on Omitted and delayed medicines. There was discussion regarding the results of this audit. Risk of omitted and delayed medicines to be placed on the Risk register.

Action: Risk to be added to the Risk Register. Risk to be flagged on next Patient Safety Report.

Decision: Noted

- **Audit: Medicines Optimisation for Paediatric Patients with Learning Disability Attending Chelsea and Westminster Hospital**

Audit relating to Medicines Optimisation for Paediatric Patients with Learning Disability Attending Chelsea and Westminster Hospital

Decision: Noted

- **Audit: Re-audit to determine whether patients at Chelsea and Westminster are prescribed intravenous immunoglobulin (IVIg) according to the Department of Health (DoH) guidelines**

Audit relating to determine whether patients at Chelsea and Westminster are prescribed intravenous immunoglobulin (IVIg) according to the Department of Health (DoH) guidelines

Decision: Noted

- **Trust Medication Safety Bulletin - June 2017**

Trust Medication Safety Bulletin - June 2017

Decision: Noted

- **MHRA Update - June 2017**

MHRA drug Safety Update for June 2017. It was noted regarding the Brimonidine (Mirvaso) gel: Risk of Systemic cardiovascular effects.

Action: To be disseminated to the Dermatologists at both sites.

Decision: Noted

4.7 Meeting minutes for noting

- **Homecare Medicines Group Meeting Minutes - June 2017**

Minutes for Homecare Medicines Group Meeting - June 2017

Decision: Noted

- **HIV/GUM Directorate - Medicines Sub-Group Meeting - March 2017**

Minutes for HIV/GUM Directorate - Medicines Sub-Group Meeting - March 2017

Decision: Noted

- **HIV/GUM Directorate - Medicines Sub-Group Meeting - April 2017**

Minutes for HIV/GUM Directorate - Medicines Sub-Group Meeting - April 2017

Decision: Noted

- **HIV/GUM Directorate - Medicines Sub-Group Meeting - May 2017**



**Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group**

Minutes for HIV/GUM Directorate - Medicines Sub-Group Meeting - May 2017

Decision: Noted

- **HIV/GUM Directorate - Medicines Sub-Group Meeting - June 2017**

Minutes for HIV/GUM Directorate - Medicines Sub-Group Meeting - June 2017

Decision: Noted

4.8 Additional papers to go to Trust patient Safety Group

Nil

5. Any other business

5.1 Prescribing of Duavive within the Trust

5.2 Change in low molecular weight heparins (LMWH) agents

5.3 Manufacturer delays

6. Date of next meeting

Date: Monday 11th September 2017

Time: 8am-9am

Location: Board Room (CWH Site) and Meeting Room A (WMUH Site via video conferencing)

Closing date: 18th August 2017